Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ABL2 | P42684 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201570 | 0.84 | MEN1 (0.40) | MEN1KMT2ARIPK2L3MBTL1MAPT | |
| SCHEMBL14688275 | 0.84 | MEN1 (0.52) | MEN1KMT2ARIPK2L3MBTL1MAPT | |
| SCHEMBL16279868 | 0.83 | PTGS2 (0.36) | MEN1KMT2AL3MBTL1MAPK14POLB | |
| SCHEMBL14688102 | 0.83 | TRPV1 (0.38) | L3MBTL1MAPTMAPK1RECQLPRKCZ | |
| SCHEMBL13946380 | 0.79 | L3MBTL1 (0.49) | MEN1KMT2ARIPK2L3MBTL1MAPT | |
| SCHEMBL15007058 | 0.79 | ALDH1A1 (0.40) | MEN1KMT2ARIPK2L3MBTL1MAPT | |
| SCHEMBL10363266 | 0.77 | RAB9A (0.49) | MEN1KMT2AL3MBTL1MAPTMAPK1 | |
| SCHEMBL28708329 | 0.76 | TP53 (0.46) | MEN1KMT2AL3MBTL1MAPTMAPK1 | |
| SCHEMBL4205964 | 0.76 | PRKCZ (0.57) | MEN1KMT2ARIPK2L3MBTL1MAPT | |
| SCHEMBL15022042 | 0.76 | POLB (0.38) | MEN1KMT2AL3MBTL1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-9458154-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-10-04 | — | — | US | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20150057273-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| EP-2788345-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | Chiesi Farmaceutici S.p.A. (IT) | 2014-10-15 | — | — | EP | disclosed |
| EP-2303267-B1 | POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES | PFIZER LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| EP-2303267-B1 | POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES | PFIZER LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| WO-2013083206-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| US-8222273-B2 | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases | PFIZER LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222273-B2 | Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases | PFIZER LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | PFIZER LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | PFIZER LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003848-A1 | Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases | CYP1B1, UBE2V1, CYP4B1 | MEN1 4868/4885KMT2A 3490/4885RIPK2 3840/4885 |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | MAPK15, MAPK1, MAP3K15 | MEN1 4810/4885KMT2A 3635/4885RIPK2 301/4885 |
| US-20150057273-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK4 | MEN1 4726/4885KMT2A 3343/4885RIPK2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.